89bio, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2025-10-30: Form 8-K; Period of report 2025-10-30; Description 1.02 Termination of a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 3.03 Material Modification to Rights of Security Holders; 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Details 1.02.
- 2025-09-18: Form 8-K; Period of report 2025-09-17; Description 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events; Details 1.01.
- 2025-08-07: Form 8-K; Period of report 2025-08-07; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2025-05-30: Form 8-K; Period of report 2025-05-28; Description 5.07 Submission of Matters to a Vote of Security Holders; Details 5.07.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2025-10-30 | 8-K | 2025-10-30 | 1.02 Termination of a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 3.03 Material Modification to Rights of Security Holders; 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 1.02 The information contained in the Introductory Note of this Current Report on Form 8-K is incorporated by reference into this Item 1.02. 2.01 The information contained in the Introductory Note and Items 1.02, 5.01 and 5.03 of this Current Report on Form 8-K is incorporated by reference into this Item 2.01. 3.01 The information contained in the Introductory Note and Item 2.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.01. 3.03 The information contained in the Introductory Note and Items 2.01, 3.01, 5.01 and 5.03 of this Current Report on Form 8-K is incorporated by reference into this Item 3.03. 5.01 The information contained in the Introductory Note and Items 2.01, 5.02 and 5.03 of this Current Report on Form 8-K is incorporated by reference into this Item 5.01. 5.02 The information contained in the Introductory Note and Item 2.01 of this Current Report on Form 8-K is incorporated by reference into this Item 5.02. 5.03 Pursuant to the terms of the Merger Agreement, at the Effective Time, the Company’s certificate of incorporation and bylaws were amended and restated in their entirety in the forms filed as Exhibits 3.1 and 3.2, respectively, to this Current Report on Form 8-K, and are incorporated herein by reference. | d48446d8k.htm |
| 2025-09-18 | 8-K | 2025-09-17 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On September 18, 2025, the Company issued a press release announcing the execution of the Merger Agreement. | d143212d8k.htm |
| 2025-08-07 | 8-K | 2025-08-07 | 2.02 Results of Operations and Financial Condition | 2.02 On August 7, 2025, 89bio, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025. | d915354d8k.htm |
| 2025-05-30 | 8-K | 2025-05-28 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On Wednesday, May 28, 2025, 89bio, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) at 9:00 a.m. | d65075d8k.htm |
| 2025-05-01 | 8-K | 2025-05-01 | 2.02 Results of Operations and Financial Condition | 2.02 On May 1, 2025, 89bio, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2025. | d919727d8k.htm |
| 2025-04-09 | 8-K | 2025-04-09 | 7.01 Regulation FD Disclosure | 7.01 On April 9, 2025, the Company made available an updated corporate presentation on the Company’s website. | d871327d8k.htm |
| 2025-02-27 | 8-K | 2025-02-27 | 2.02 Results of Operations and Financial Condition | 2.02 On February 27, 2025, 89bio, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2024. | d909955d8k.htm |
| 2025-02-04 | 8-K | 2025-01-31 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 31, 2025, the Compensation Committee of the Board of Directors of 89bio, Inc. (the “Company”) approved the grant of 200,000 restricted stock units (“RSUs”) to Rohan Palekar, the Chief Executive Officer of the Company. | d826522d8k.htm |
| 2025-01-29 | 8-K | 2025-01-28 | 1.01 Entry into a Material Definitive Agreement | 1.01 On January 28, 2025, 89bio, Inc. (the “Company”) entered into an underwriting agreement (“Underwriting Agreement”) with Goldman Sachs & Co. LLC, Leerink Partners LLC, BofA Securities, Inc., as the representatives of the underwriters named therein (the “Underwriters”), to issue and sell 21,671,428 shares of the Company’s common stock at a public offering price of $8.75 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 6,900,000 shares of the Company’s common stock (the “Pre-Funded Warrants”) at a public offering price of $8.749 per share, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each Pre-Funded Warrant (the “Offering”). | d197264d8k.htm |
| 2025-01-13 | 8-K | 2025-01-13 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 The information set forth below under “Preliminary Financial Information for the Year Ended December 31, 2024” in Item 8.01 is incorporated by reference herein. 8.01 On January 13, 2025, 89bio, Inc. (the “Company”) issued a press release providing a corporate update and business outlook for 2025. | d903952d8k.htm |
| 2024-12-16 | 8-K | 2024-12-12 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On December 12, 2024, the Board of Directors of 89bio, Inc. (the “Company”) approved the grant of restricted stock units to certain employees of the Company for retention purposes (the “Retention RSUs”). | d892029d8k.htm |
| 2024-11-14 | 8-K | 2024-11-12 | 1.01 Entry into a Material Definitive Agreement | 1.01 On November 12, 2024, 89bio, Inc. (the “Company”) entered into an underwriting agreement (“Underwriting Agreement”) with Goldman Sachs & Co. LLC, Leerink Partners LLC, and Evercore Group L.L.C., as the representatives of the underwriters named therein (the “Underwriters”), to issue and sell 11,455,882 shares of the Company’s common stock at a public offering price of $8.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 3,250,000 shares of the Company’s common stock (the “Pre-Funded Warrants”) at a public offering price of $8.499 per share, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each Pre-Funded Warrant (the “Offering”). | d912933d8k.htm |
| 2024-11-07 | 8-K | 2024-11-07 | 2.02 Results of Operations and Financial Condition | 2.02 On November 7, 2024, 89bio, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2024. | d848707d8k.htm |
| 2024-10-30 | 8-K/A | 2024-07-30 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On October 29, 2024, the Board appointed Dr. McWherter to serve on the Board’s Nominating and Corporate Governance Committee and Science and Technology Committee, effective October 29, 2024. | d148660d8ka.htm |
| 2024-10-03 | 8-K | 2024-09-30 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 2.03 The information set forth in Item 1.01 above regarding the Loan Agreement is incorporated by reference into this Item 2.03. 3.02 The information set forth in Item 1.01 above regarding the Warrant and the Conversion Shares is incorporated by reference into this Item 3.02. | d810672d8k.htm |
| 2024-08-07 | 8-K | 2024-07-30 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 5.02 On August 7, 2024, 89bio, Inc. (the “Company”) announced that the board of directors (the “Board”) of the Company appointed Francis Sarena as the Company’s Chief Operating Officer, effective August 5, 2024. 7.01 On August 7, 2024, the Company issued a press release announcing Mr. Sarena’s appointment. | d856529d8k.htm |
| 2024-08-05 | 8-K | 2024-07-30 | 2.02 Results of Operations and Financial Condition; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 2.02 On August 5, 2024, 89bio, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2024. 5.02 On July 30, 2024, the board of directors (the “Board”) of the Company appointed Charles McWherter, Ph.D. as a member of the Board. 7.01 On August 5, 2024, the Company issued a press release announcing Dr. McWherter’s appointment. | d879198d8k.htm |
| 2024-05-31 | 8-K | 2024-05-29 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On Wednesday, May 29, 2024, 89bio, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”) at 9:00 a.m. | d830712d8k.htm |
| 2024-05-09 | 8-K | 2024-05-09 | 2.02 Results of Operations and Financial Condition | 2.02 On May 9, 2024, 89bio, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024. | d793786d8k.htm |
| 2024-04-17 | 8-K | 2024-04-13 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 5.02 On April 13, 2024, the board of directors (the “Board”) of 89bio, Inc. (the “Company”) appointed Martin Babler as a member of the Board. 7.01 On April 17, 2024, the Company issued a press release announcing Mr. Babler’s appointment. | d818743d8k.htm |
| 2024-04-10 | 8-K | 2024-04-04 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d818064d8k.htm |
| 2024-02-29 | 8-K | 2024-02-29 | 2.02 Results of Operations and Financial Condition | 2.02 On February 29, 2024, 89bio, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2023. | d803143d8k.htm |
| 2023-12-08 | 8-K | 2023-12-06 | 1.01 Entry into a Material Definitive Agreement | 1.01 On December 6, 2023, 89bio, Inc. (the “Company”) entered into an underwriting agreement (“Underwriting Agreement”) with BofA Securities, Inc. and Leerink Partners LLC, as the representatives of the underwriters named therein (the “Underwriters”), to issue and sell 15,135,135 shares of the Company’s common stock at a public offering price of $9.25 per share and, in lieu of common stock to a certain investor, pre-funded warrants to purchase 1,081,081 shares of the Company’s common stock (the “Pre-Funded Warrants”) at a public offering price of $9.249 per share, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each Pre-Funded Warrant (the “Offering”). | d636644d8k.htm |
| 2023-12-06 | 8-K | 2023-12-04 | 8.01 Other Events | 8.01 On December 4, 2023, the Company made available an updated corporate presentation on the Company’s website. | d621096d8k.htm |
| 2023-12-04 | 8-K | 2023-12-04 | 7.01 Regulation FD Disclosure | 7.01 On December 4, 2023, 89bio, Inc. (the “Company”) issued a press release announcing alignment with the U.S. Food and Drug Administration and the European Medicines Agency on the Company’s Phase 3 program for pegozafermin in nonalcoholic steatohepatitis. | d627343d8k.htm |
| 2023-11-27 | 8-K | 2023-11-27 | 7.01 Regulation FD Disclosure | 7.01 On November 27, 2023, 89bio, Inc. (the “Company”) issued a press release announcing positive long-term data from its Phase 2b trial (ENLIVEN) of pegozafermin in patients with nonalcoholic steatohepatitis (NASH). | d494058d8k.htm |
| 2023-11-14 | 8-K | 2023-11-09 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | d281066d8k.htm | |
| 2023-11-09 | 8-K | 2023-11-08 | 2.02 Results of Operations and Financial Condition | 2.02 On November 8, 2023, 89bio, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023. | d286668d8k.htm |
| 2023-08-15 | 8-K | 2023-08-10 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On August 10, 2023, Gregory Grunberg notified the board of directors (the “Board”) of 89bio, Inc. (the “Company”) of his intent to resign as a member of the Board and its committees, effective immediately. | d538227d8k.htm |
| 2023-08-09 | 8-K | 2023-08-09 | 2.02 Results of Operations and Financial Condition | 2.02 On August 9, 2023, 89bio, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023. | d513957d8k.htm |
| 2023-06-09 | 8-K | 2023-06-05 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders | 5.03 At the Annual Meeting, the Company’s stockholders approved an amendment to the Company’s Second Amended and Restated Certificate of Incorporation (the “Second Amended and Restated Certificate of Incorporation”) to increase the number of authorized shares of Common Stock from 100,000,000 to 200,000,000 and to increase the total number of authorized shares from 110,000,000 to 210,000,000 (the “Amendment”). 5.07 At the Annual Meeting, each of the Company’s director nominees was elected and the other proposals voted on were approved. | d585312d8k.htm |
| 2023-05-04 | 8-K | 2023-05-04 | 2.02 Results of Operations and Financial Condition | 2.02 On May 4, 2023, 89bio, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2023. | d357120d8k.htm |
| 2023-03-28 | 8-K | 2023-03-23 | 1.01 Entry into a Material Definitive Agreement | 1.01 On March 23, 2023, 89bio, Inc. (the “Company”) entered into an underwriting agreement (“Underwriting Agreement”) with BofA Securities, Inc., SVB Securities, LLC and Evercore Group L.L.C., as the representatives of the underwriters named therein (the “Underwriters”), to issue and sell 16,923,077 shares of the Company’s common stock at a public offering price of $16.25 per share (the “Offering”). | d489734d8k.htm |
| 2023-03-22 | 8-K | 2023-03-22 | 7.01 Regulation FD Disclosure | 7.01 On March 22, 2023, 89bio, Inc. (the “Company”) issued a press release announcing positive topline data from its Phase 2b trial (ENLIVEN) of pegozafermin (previously BIO89-100) in patients with nonalcoholic steatohepatitis (NASH). | d486980d8k.htm |
| 2023-03-10 | 8-K | 2023-03-10 | 2.02 Results of Operations and Financial Condition | 2.02 On March 10, 2023, 89bio, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2022. | d469201d8k.htm |
| 2023-02-16 | 8-K | 2023-02-15 | 1.01 Entry into a Material Definitive Agreement | 1.01 On February 15, 2023, 89bio, Inc. (the “Company”) entered into Amendment No. 1 to the Sales Agreement, dated March 25, 2021 (as amended, the “Sales Agreement”), with SVB Securities LLC and Cantor Fitzgerald & Co. (the “Sales Agents”), pursuant to which the Company may offer and sell from time to time shares of the Company’s common stock, par value $0.001 (the “Shares”), through the Sales Agents. | d422452d8k.htm |
| 2023-02-15 | 8-K | 2023-02-15 | 8.01 Other Events | 8.01 On February 15, 2023, 89bio, Inc. (the “Company”) will participate in a fireside chat and one-on-one investor meetings at the SVB Securities Global Biopharma Conference. | d418158d8k.htm |
| 2023-02-02 | 8-K/A | 2023-01-04 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 2.03 The information set forth in Item 1.01 above regarding the Loan Agreement is incorporated by reference into this Item 2.03. 3.02 The information set forth in Item 1.01 above regarding the Warrant and the Conversion Shares is incorporated by reference into this Item 3.02. | d650071d8ka.htm |
| 2023-01-06 | 8-K | 2023-01-04 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 2.03 The information set forth in Item 1.01 above regarding the Loan Agreement is incorporated by reference into this Item 2.03. 3.02 The information set forth in Item 1.01 above regarding the Warrant and the Conversion Shares is incorporated by reference into this Item 3.02. | d445245d8k.htm |
| 2022-11-10 | 8-K | 2022-11-10 | 2.02 Results of Operations and Financial Condition | 2.02 On November 10, 2022, 89bio, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022. | d392870d8k.htm |
| 2022-08-11 | 8-K | 2022-08-11 | 2.02 Results of Operations and Financial Condition | 2.02 On August 11, 2022, 89bio, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2022. | d385983d8k.htm |
| 2022-07-01 | 8-K | 2022-06-28 | 1.01 Entry into a Material Definitive Agreement | 1.01 On June 28, 2022, 89bio, Inc. (the “Company”) entered into an underwriting agreement (“Underwriting Agreement”) with BofA Securities, Inc. and SVB Securities, LLC, as the representatives of the underwriters named therein (the “Underwriters”), to issue and sell 18,675,466 shares of the Company’s common stock and accompanying warrants to acquire 9,337,733 shares of the Company’s common stock (the “Warrants”) at a combined public offering price of $3.55 and, in lieu of common stock to certain investors, pre-funded warrants to purchase 7,944,252 shares of common stock (the “Pre-Funded Warrants”) and accompanying Warrants to purchase up to 3,972,126 shares of common stock at a combined public offering price of $3.549 per share, which represents the combined public offering price for a share of common stock and accompanying warrant, less the $0.001 per share exercise price for each Pre-Funded Warrant (the “Offering”). | d376547d8k.htm |
| 2022-06-28 | 8-K | 2022-06-28 | 8.01 Other Events | 8.01 On June 28, 2022, 89bio, Inc. (the “Company”) issued a press release announcing positive initial data from its Phase 2 trial (ENTRIGUE) of pegozafermin (previously BIO89-100) in patients with severe hypertriglyceridemia (SHTG). | d362352d8k.htm |
| 2022-06-07 | 8-K | 2022-06-01 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On Wednesday, June 1, 2022, 89bio, Inc. (the “Company”) held its 2022 Annual Meeting of Stockholders (the “2022 Annual Meeting”) at 9:00 a.m. | d336615d8k.htm |
| 2022-05-11 | 8-K | 2022-05-11 | 2.02 Results of Operations and Financial Condition | 2.02 On May 11, 2022, 89bio, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2022. | d330218d8k.htm |
| 2022-03-24 | 8-K | 2022-03-24 | 2.02 Results of Operations and Financial Condition | 2.02 On March 24, 2022, 89bio, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2021. | d338206d8k.htm |
| 2022-03-04 | 8-K/A | 2022-02-17 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On February 17, 2022, the board of directors (the “Board”) of 89bio, Inc. (the “Company”) appointed Edward Morrow Atkinson III as a member of the Board. | d313986d8ka.htm |
| 2022-02-24 | 8-K | 2022-02-17 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On February 17, 2022, the board of directors (the “Board”) of 89bio, Inc. (the “Company”) appointed Edward Morrow Atkinson III as a member of the Board, effective November 1, 2021. | d243535d8k.htm |
| 2022-01-24 | 8-K | 2022-01-24 | 8.01 Other Events | 8.01 On January 24, 2022, the Company issued a press release announcing the topline results from an expansion cohort of the Phase 1b/2a trial of pegozafermin for the treatment of nonalcoholic steatohepatitis. | d300501d8k.htm |
| 2021-11-12 | 8-K | 2021-11-11 | 2.02 Results of Operations and Financial Condition | 2.02 On November 11, 2021, 89bio, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2021. | d260057d8k.htm |
| 2021-11-03 | 8-K | 2021-10-31 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On October 31, 2021, the board of directors (the “Board”) of 89bio, Inc. (the “Company”) appointed Kathleen D. LaPorte as a member of the Board, effective November 1, 2021. | d239863d8k.htm |
| 2021-08-12 | 8-K | 2021-08-12 | 2.02 Results of Operations and Financial Condition | 2.02 On August 12, 2021, 89bio, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2021. | d120752d8k.htm |
| 2021-07-30 | 8-K | 2021-07-28 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On July 28, 2021, Ms. Anat Naschitz notified the board of directors (the “Board”) of 89bio, Inc. (the “Company”) of her intent to resign as a member of the Board, effective July 30, 2021. | d208099d8k.htm |
| 2021-06-10 | 8-K | 2021-06-10 | 8.01 Other Events | 8.01 On June 10, 2021 89bio, Inc. (the “Company”) made available an updated corporate presentation on the Company’s website. | d177067d8k.htm |
| 2021-06-04 | 8-K | 2021-06-02 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On Wednesday, June 2, 2021, 89bio, Inc. (the “Company”) held its 2021 Annual Meeting of Stockholders (the “2021 Annual Meeting”) at 9:00 a.m., Pacific Time. | d151093d8k.htm |
| 2021-06-04 | 8-K | 2021-05-28 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 2.03 The information set forth in Item 1.01 above regarding the Amendment is incorporated by reference into this Item 2.03. 3.02 The information set forth in Item 1.01 above regarding the Warrants is incorporated by reference into this Item 3.02. | d127486d8k.htm |
| 2021-05-13 | 8-K | 2021-05-12 | 2.02 Results of Operations and Financial Condition | 2.02 On May 12, 2021, 89bio, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2021. | d159558d8k.htm |
| 2021-03-24 | 8-K | 2021-03-24 | 2.02 Results of Operations and Financial Condition | 2.02 On March 24, 2021, 89bio, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2020. | d318413d8k.htm |
| 2020-11-10 | 8-K | 2020-11-10 | 2.02 Results of Operations and Financial Condition | 2.02 On November 10, 2020, 89bio, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2020. | d927940d8k.htm |
| 2020-10-05 | 8-K | 2020-10-05 | 8.01 Other Events | 8.01 On October 5, 2020, 89bio, Inc. (the “Company”) made available an updated corporate presentation on the Company’s website. | d49854d8k.htm |
| 2020-09-14 | 8-K | 2020-09-14 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act or the Exchange Act, except as shall be expressly set forth in such registration statement or filing. 8.01 The Company from time to time presents and/or distributes to the investment community slide presentations to provide updates and summaries of its business. | d20544d8k.htm |
| 2020-06-26 | 8-K | 2020-06-22 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On Monday, June 22, 2020, 89bio, Inc. (the “Company”) held its 2020 Annual Meeting of Stockholders (the “2020 Annual Meeting”) at 9:00 a.m., Pacific Time. | d947702d8k.htm |
| 2020-06-04 | 8-K | 2020-06-01 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On June 1, 2020, the board of directors (the “Board”) of 89bio, Inc. (the “Company”) appointed Lota Zoth as a member of the Board. | d936091d8k.htm |
| 2020-05-13 | 8-K | 2020-05-13 | 2.02 Results of Operations and Financial Condition | 2.02 On May 13, 2020, 89bio, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2020. | d932036d8k.htm |
| 2020-05-04 | 8-K | 2020-04-15 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 89bio, Inc. (the “Company”) entered into revised employment letter agreements with each of Rohan Palekar, Ryan Martins, Hank Mansbach and Quoc Le-Nguyen (the “Executives”) in order to provide the Executives with severance protections that are more in line with market practices. | d898684d8k.htm |
| 2020-04-23 | 8-K | 2020-04-17 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 (a) Dismissal of Previous Independent Registered Public Accounting Firm. | d919569d8k.htm |
| 2020-04-13 | 8-K | 2020-04-13 | 8.01 Other Events | 8.01 On April 13, 2020, the Company issued a press release announcing that it closed enrollment in its Phase 1b/2a trial for nonalcoholic steatohepatitis with 98% of patients enrolled and has delayed initiation of its severe hypertriglyceridemia trial due to the ongoing COVID-19 pandemic. | d917401d8k.htm |
| 2020-04-13 | 8-K | 2020-04-07 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 2.03 The information set forth in Item 1.01 above regarding the Loan Agreement is incorporated by reference into this Item 2.03. 3.02 The information set forth in Item 1.01 above regarding the Warrants is incorporated by reference into this Item 3.02. | d912211d8k.htm |
| 2020-03-26 | 8-K | 2020-03-23 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 23, 2020, the board of directors (the “Board”) of 89bio, Inc. (the “Company”) appointed Steven M. Altschuler, M.D. to the Board as Chairman. | d140983d8k.htm |
| 2020-03-18 | 8-K | 2020-03-18 | 2.02 Results of Operations and Financial Condition | 2.02 On March 18, 2020, 89bio, Inc. issued a press release announcing its financial results for the quarter and year ended December 31, 2019. | d901592d8k.htm |
| 2019-12-31 | 8-K | 2019-12-24 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 On December 24, 2019, the Audit Committee of the Board of Directors (the “Audit Committee”) of 89bio, Inc. dismissed Brightman Almagor Zohar & Co., a Firm in the Deloitte Global Network (“Deloitte Israel”) as the independent registered public accounting firm of the Company, effective immediately. | d832431d8k.htm |
| 2019-12-18 | 8-K | 2019-12-18 | 2.02 Results of Operations and Financial Condition | 2.02 On December 18, 2019, 89bio, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2019. | d848806d8k.htm |
| 2019-12-16 | 8-K | 2019-12-12 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On December 12, 2019, Mr. Tomer Kariv notified the board of directors (the “Board”) of 89bio, Inc. (the “Company”) of his intent to resign as a member of the Board, effective immediately. | d839091d8k.htm |
| 2019-11-15 | 8-K | 2019-11-13 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 5.03 On November 13, 2019, 89bio, Inc. (the “Company”) filed a Second Amended and Restated Certificate of Incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the Company’s initial public offering (the “IPO”) of its common stock, par value $0.001 per share. | d829788d8k.htm |